Challenges and Opportunities to Manage Depression During the Menopausal Transition and Beyond

Soares, Cláudio N.; Frey, Benício N.

doi:10.1016/j.psc.2010.01.007

Cited by 36 publications

(24 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another placebo-controlled study, the capability of transdermal estradiol to improve states of anxiety was reported by the use of State Trait Anxiety Scale, during a 3month period of treatment (25). Using transdermal estradiol, as well as serotonergic and noradrenergic antidepressants, was an efficacious strategy in the treatment of depression and vasomotor symptoms in symptomatic women (26). Similarly, we found that the combination of transdermal estradiol and norethisterone was better than placebo for improvement of depression and anxiety scores.…”

Section: Discussionsupporting

confidence: 51%

Semptomatik Postmenopozal Kadınlarda İki Farklı Hormon Terapisinin Ruhsal Durum Üzerine Etkilerinin Karşılaştırılması

...

2012

npa

View full text Add to dashboard Cite

Objective: To investigate the effects of two different hormone therapies on menopausal symptoms, depression and anxiety scores in women with symptomatic natural menopause.Methods: 183 patients completed the study. Group I patients were treated with transdermal estradiol and oral norethisterone acetate. Group II patients were treated with oral continuous combination of noretbisterone and estradiol bemibydrate. Group III (control group) patients were administered placebo. Tbe treatment protocols were used for three months in all groups. Menopausal, depression and anxiety symptoms of the patients were assessed using the Kupperman scale, Hamilton Depression Rating Scale (HDRS) and the Beck Anxiety Inventory (BAI) before and at tbe end of treatment Results: Significant improvement was observed in menopausal symptoms, depression and anxiety scores in all groups at the end of three montbs of therapy (p<0.001). When the three groups were compared for all parameters before and after treatment, groups I and II showed better results tban group III (p<0.001).Conclusion: Transdermal or oral estradiol in combination witb norethisterone improves scores of menopausal, depression and anxiety symptoms in women with symptomatic natural menopause. (Archives of Neuropsychiatry 2012:49:39-43) Amaç: Semptomatik dogal menopoz dönemindeki kadmlarda iki farkli hormón tedavisinin etkileri ile control grubunda menopoz, depresyon ve anksiyete belirtilerinin kar §ila §tinlmasi amaçlanmi §tir. Yöntem 1er: Yüz seksen ijç hasta çaliçmayi tamamladi. I. Gruptaki hastalar oral noretisteron asetat ve transdermal östradiol ile tedavi edildiler. II. Gruptaki hastalar oral noretisteron ve östradiol hemihidrat kombinasyonu ile tedavi edildiler. III. Gruptaki hastalar (control grubu) placebo uygulandi. Tedavi protokolij tüm gruplarda 3 ay uygulandi. Hastalarin menopozal, depresyon ve anksiyete belirtileri tedavinin baçinda ve tedaviriin sonunda Kupperman Öicegi, Hamilton Depresyon Öicegi ve Beck Anksiyete Öicegi ile degerlendirildi. Bulgular: Üc aylik tedavi süresinin sonunda tijm gruplarda menopoz, depresyon ve anksiyete belirtilerinin anlamli ölcüde azaldigi (p<0,001) gözlendi. Tedavinin baçlangici ve sonunda zamana göre üc grubunun tüm degerlerini kar §ila §tirdigimizda I ve II grubun degerlerinin III. gruba gore daha lyi oldugu bulundu (p< 0,001).Sonuç: Trandermal veya oral östradiol ile noretisteron kombinasyonu, semptomatik dogal menopozlu kadinlarda menopoz ve depresyon ve anksiyete degerlerini iyileçtirmektedir. (NöropsikiyatriAr^ivi2012:49:39-43) Anahtar kelimeler: Menopoz, östradiol, noretisteron asetat, psikiyatri, depresyon

show abstract

Section: Discussionsupporting

confidence: 51%

Semptomatik Postmenopozal Kadınlarda İki Farklı Hormon Terapisinin Ruhsal Durum Üzerine Etkilerinin Karşılaştırılması

...

2012

npa

View full text Add to dashboard Cite

show abstract

“…This predominance in women is at least partly due to gonadal hormones. Further, fluctuations in levels rather than absolute levels of these hormones seem more likely to be linked with the onset of symptoms of depression (Soares and Frey 2010). …”

Section: Introductionmentioning

confidence: 99%

“…Although estrogen may be useful in helping with depression around the perimenopause (see Grigoriadis and Robinson 2007; Soares and Frey 2010), there is no consistent body of data showing its efficacy in postmenopausal depressed patients, either as a stand-alone therapy or as adjunct therapy with selective serotonin reuptake inhibitors (SSRIs) (Huttner and Shepherd 2003; Schneider et al 2001; Yalamanchili and Gallagher 2012). This is of some interest as estrogen has been shown to modulate neurotransmitter systems, including serotonergic and noradrenergic systems that are involved in mood regulation (McEwen and Alves 1999; Rubinow et al 1998).…”

Section: Introductionmentioning

confidence: 99%

Influence of acute or chronic administration of ovarian hormones on the effects of desipramine in the forced swim test in female rats

Shah

Frazer

2014

Psychopharmacology

View full text Add to dashboard Cite

Rationale Gender may influence antidepressant (AD) treatment outcome. In order to address this pre-clinically, the potential effects of ovarian hormones on AD treatment in ovariectomized female rats were investigated. Objectives In the first study, the effect of acute administration of estrogen and progesterone on the antidepressant-like effects of desipramine (DMI), a selective norepinephrine reuptake inhibitor (SNRI), was investigated in the forced swimming test (FST). In the second study, the effect of chronic administration of these hormones on the effects of chronically administered DMI was investigated. Results In the acute study, the hormones blocked the effects of DMI in the FST as demonstrated by the absence of either a reduction in immobility or an increase in climbing behavior in animals treated with DMI in combination with the hormones. Concentration-response experiments on hippocampal synaptosomes revealed no changes in the Km or Bmax for uptake of 3H-NE in hormone-treated rats. In the chronic study, the antidepressant-like effects of DMI in the FST were not blocked by chronic administration of hormones. Interestingly, the hormones affected the serum concentrations of DMI. These levels were significantly higher in animals receiving 10 or 15 mg/kg/day in hormone-treated rats as compared to those with placebo. Conclusions Acute administration of hormones blocked the effects of DMI (given three times over 24 h) in the FST. However, chronic administration of these hormones failed to block the effects of chronically administered DMI (at a dose that produces clinically relevant serum concentrations).

show abstract

“…Of the 31 women, 13 had a history of PMS. The effects of sEPT with different progesterone doses (estradiol valerate 2 mg/d + vaginal progesterone at either 800 or 400 mg/d on days [15][16][17][18][19][20][21][22][23][24][25][26][27][28] were compared with those of ET alone (estradiol valerate 2 mg/d + placebo). More negative mood in the EPT phase relative to the estrogen-only phase was found only in women with no history of PMS and with the lower dose of progesterone (400 mg).…”

Section: Ept and Moodmentioning

confidence: 99%

Hormone therapy and mood in perimenopausal and postmenopausal women

2015

View full text Add to dashboard Cite

show abstract

Challenges and Opportunities to Manage Depression During the Menopausal Transition and Beyond

Cited by 36 publications

References 77 publications

Semptomatik Postmenopozal Kadınlarda İki Farklı Hormon Terapisinin Ruhsal Durum Üzerine Etkilerinin Karşılaştırılması

Semptomatik Postmenopozal Kadınlarda İki Farklı Hormon Terapisinin Ruhsal Durum Üzerine Etkilerinin Karşılaştırılması

Influence of acute or chronic administration of ovarian hormones on the effects of desipramine in the forced swim test in female rats

Hormone therapy and mood in perimenopausal and postmenopausal women

Contact Info

Product

Resources

About